Management of Hemoglobin Not Improving After Blood Transfusion in a Patient on Eliquis

Initial Assessment

Evaluate for active bleeding by monitoring vital signs, physical examination findings, and laboratory parameters in patients on apixaban (Eliquis) who have not shown improvement in hemoglobin levels after blood transfusion, as recommended by the American Society of Anesthesiologists 1
Check for transfusion reactions that may be contributing to hemolysis and stop transfusion immediately if suspected, following guidelines from the American Association of Blood Banks 1
Assess hemoglobin concentration before and after each unit of RBC transfused using laboratory measurement or near-patient testing, as suggested by the American College of Pathologists 1
Review peripheral blood smear to identify potential causes of persistent anemia, such as hemolysis or schistocytes, as recommended by the American Society of Clinical Oncology 3

Major bleeding is defined as the presence of hemodynamic instability, bleeding at a critical site, or clinically overt bleeding with hemoglobin decrease ≥2 g/dL or requiring ≥2 units of RBCs, according to the American College of Cardiology 2
Non-major bleeding is characterized by the absence of the above criteria, as defined by the American College of Cardiology 2

Stop Eliquis (apixaban) immediately in patients with major bleeding, as recommended by the American College of Cardiology 2
Provide local measures to control bleeding and supportive care with volume resuscitation, following guidelines from the American Heart Association 2
Consider administering prothrombin complex concentrate (PCC) for urgent reversal of apixaban in life-threatening bleeding, as suggested by the American College of Cardiology 2
Follow a restrictive transfusion approach with a hemoglobin threshold of 7 g/dL for most patients, as recommended by the American Society of Anesthesiologists 1 and the Society of Critical Care Medicine 4, 5
Consider a higher threshold of 8 g/dL for patients with ischemic heart disease, as suggested by the American College of Cardiology 6 and the American Heart Association 1

Evaluate for ongoing occult bleeding sources, such as gastrointestinal or retroperitoneal bleeding, as recommended by the American College of Cardiology 2
Check for drug-induced hemolysis or immune-mediated hemolysis, as suggested by the American Society of Clinical Oncology 3
Assess for iron, B12, or folate deficiency that may impair response to transfusion, as recommended by the American Society of Clinical Oncology 7 and the European Crohn's and Colitis Organisation 8
Consider delayed hemolytic transfusion reaction with hyperhemolysis syndrome, as suggested by the American Society of Hematology 9
Evaluate for dilutional anemia from excessive IV fluid administration, as recommended by the American Society of Anesthesiologists 1

For suspected immune-mediated hemolysis, consider immunosuppressive therapy, such as corticosteroids or IVIG, as recommended by the American Society of Hematology 9
Consider erythropoietin therapy only if anemia is not related to acute bleeding, as suggested by the American Society of Clinical Oncology 7

Restart Eliquis only after bleeding is controlled and the source identified and addressed, as recommended by the American College of Cardiology 2
Consider factors such as whether the bleeding occurred at a critical site, patient's risk of rebleeding versus thrombotic risk, and whether the source of bleeding has been identified and treated, as suggested by the American College of Cardiology 2

Perform serial hemoglobin measurements to assess response to interventions, as recommended by the American Society of Anesthesiologists 1
Monitor for signs of continued bleeding, such as tachycardia, hypotension, or oliguria, as suggested by the American Society of Anesthesiologists 1
Assess for transfusion-related complications, including volume overload, transfusion reactions, and transfusion-associated circulatory overload, as recommended by the American Association of Blood Banks 1